Summit Therapeutics Inc.
SMMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $42 | $37 | $25 | $14,940 |
| Gross Profit | -$42 | -$37 | -$25 | -$14,940 |
| % Margin | – | – | – | – |
| R&D Expenses | $131,096 | $208,021 | $51,265 | $51,400 |
| G&A Expenses | $0 | $360,416 | $15,586 | $14,410 |
| SG&A Expenses | $103,073 | $360,379 | $15,586 | $14,410 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$196 |
| Operating Expenses | $234,169 | $568,400 | $66,851 | $65,614 |
| Operating Income | -$234,211 | -$568,437 | -$66,851 | -$65,614 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,418 | $2,729 | $3,938 | $4,438 |
| Pre-Tax Income | -$231,793 | -$565,708 | -$62,913 | -$61,176 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$231,793 | -$565,708 | -$62,913 | -$61,203 |
| % Margin | – | – | – | – |
| EPS | -0.31 | -0.76 | -0.085 | -0.083 |
| % Growth | 59.2% | -792% | -2.7% | – |
| EPS Diluted | -0.31 | -0.76 | -0.085 | -0.083 |
| Weighted Avg Shares Out | 743,416 | 742,615 | 738,076 | 737,500 |
| Weighted Avg Shares Out Dil | 743,416 | 742,615 | 738,076 | 737,500 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,780 | $2,981 | $3,861 | $13,466 |
| Interest Expense | $0 | $0 | $0 | $9 |
| Depreciation & Amortization | $42 | $37 | $25 | -$67 |
| EBITDA | -$231,751 | -$565,671 | -$62,888 | -$61,145 |
| % Margin | – | – | – | – |